Business Wire (May 9, 2013)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,009 people get BCRX articles and Market Currents by email alert.
Get email alerts on BCRX »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Business Wire (May 7, 2013)
-
-
-
Business Wire (Apr 23, 2013)
-
-
Business Wire (Apr 16, 2013)
-
-
-
-
-
Business Wire (Apr 1, 2013)
-
Business Wire (Mar 25, 2013)
-
-
-
Business Wire (Feb 19, 2013)
-
Business Wire (Feb 5, 2013)
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
BioCryst Drug Receives Recommendation for Pediatric Approval in JapanMichael Murphy • Mon, Sep 27, 2010 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
The Best And Worst Of Earnings SeasonBespoke Investment Group • Fri, Nov 16, 2012 -
Today's Market News To Trade On: 5 Stocks Moving On NewsMatthew Smith • Fri, Nov 9, 2012
-
-
-
-
What Moves Biotech Stocks? Ed Arce Has AnswersLife Sciences Report • Thu, Oct 18, 2012 -
-
-
-
-
BioCryst Pharmaceuticals, Inc. Q1 2010 Earnings Call TranscriptWed, Apr 28, 2010
-
BioCryst Pharmaceuticals, Inc. Q4 2009 Earnings Call TranscriptThu, Feb 4, 2010
-
BioCryst Pharmaceuticals, Inc. Q4 2007 Earnings Call TranscriptMon, Mar 24, 2008
-
Business Wire (May 9, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (Apr 23, 2013)
-
Business Wire (Apr 16, 2013)
-
at MarketWatch.com (Apr 8, 2013)
-
at MarketWatch.com (Apr 8, 2013)
-
Business Wire (Apr 1, 2013)
-
Business Wire (Mar 25, 2013)
-
Business Wire (Feb 19, 2013)
-
Business Wire (Feb 5, 2013)
-
Business Wire (Jan 2, 2013)
-
Business Wire (Dec 7, 2012)
-
Business Wire (Nov 30, 2012)
-
Business Wire (Nov 12, 2012)
-
at MarketWatch.com (Nov 8, 2012)
-
Business Wire (Nov 8, 2012)
-
Business Wire (Nov 7, 2012)
-
Business Wire (Nov 1, 2012)
-
Business Wire (Oct 30, 2012)
-
Business Wire (Oct 18, 2012)
BCRX vs. ETF Alternatives
Company Description
BioCryst Pharmaceuticals, Inc. is a biotechnology company that designs, optimizes and develops novel drugs that block key enzymes involved in cancer, viral infections and autoimmune diseases. BioCryst integrates the disciplines of biology, crystallography, medicinal chemistry and computer... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, February 19, 6:25 AM BioCryst Pharmaceuticals (BCRX): Q4 EPS of -$0.22 misses by $0.06. Revenue of $4.1M in-line. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, February 19, 12:05 AM Notable earnings before Tuesday’s open: ACT, BCRX, DCIX, FUN, GPC, MDT, MRGE, NGPC, NI, NM, ROC, SAVE, SEE, WAB, WIN, XEC, YNDX Comment! [Earnings]
- Monday, February 18, 5:30 PM Notable earnings before Tuesday’s open: ACT, BCRX, DCIX, FUN, GPC, MDT, MRGE, NGPC, NI, NM, ROC, SAVE, SEE, WAB, WIN, XEC, YNDX Comment! [Earnings]
-
Friday, January 11, 12:45 PM
Midday top 10 gainers: UPIP +31%. KGJI +20%. INFY +17%. DNDN +15%. REDF +14%. FLML +14%. BBY +12%. SIFY +11%. ICAD +10%. BCRX +10%.
Midday top 10 Losers: NEWL -29%. ARQL -15%. YOD -15%. PDEX -12%. BV -11%. RGLS -10%. FARO -9%. CENX -9%. MY -9%. STXS -9%. Comment! [On the Move] - Friday, December 7, 2012, 9:24 AM BioCryst Pharmaceuticals (BCRX) -4.1% premarket after announcing it will lay off 50% of its workforce as part of a restructuring program aimed at cutting costs while advancing its antiviral program and its program for hereditary angioedema, an immune system disorder. Comment! [Healthcare, On the Move]
-
Monday, December 3, 2012, 12:45 PM
Midday top 10 gainers: SQNS +32%. CLNT +26%. THTI +24%. RCON +16%. SGOC +15%. CYCC +14%. LTBR +13%. AXR +13%. ZAZA +13%. LPH +12%.
Midday top 10 Losers: TSRI -32%. AOL -14%. SEM -12%. GMED -10%. BCRX -10%. IMRS -9%. SARA -9%. DCTH -9%. DAIO -9%. RATE -9%. Comment! [On the Move] - Friday, November 30, 2012, 2:58 PM BioCryst (BCRX +7.5%) is up after terminating its merger agreement with private Presidio Pharmaceuticals, which was contingent on BioCryst securing $60M in financing. However, shares are well off their morning highs. BioCryst had agreed to buy Presidio in an all-stock deal once valued at $101M, but its shares had been cut in more than half since then thanks to a withdrawn application for a hepatitis drug, and the ending of trials for a flu drug. SA's PropThink expects BioCryst to remain on the hunt for fresh capital. Comment! [Healthcare, On the Move]
- Tuesday, November 27, 2012, 2:46 PM BioCryst (BCRX -4.7%) trades lower today following the announcement that its investigational new drug BCX4161 has been put on a clinical hold due to manufacturing issues. JMP Securities cut the shares to Market Perform on the news. Comment! [Healthcare, On the Move]
- Tuesday, November 20, 2012, 12:45 PM Midday top 10 gainers: SCHS +31%. KKD +21%. GBR +19%. SGOC +13%. RECV +19%. IMH +17%. DAKT +14%. BCRX +11%. DY +13%. ERII +12%. Midday top 10 Losers: IMOS -11%. BBY -12%. HNRG -11%. CLF -11%. HPQ -11%. CRMT -11%. SCVL -11%. TSL -9%. BAA -10%. ZAZA -10%. Comment!
- Thursday, November 8, 2012, 12:45 PM Midday top 10 gainers: DUSA +38%. PRMW +23%. ARX +22%. RST +22%. ES +19%. FALC +18%. UPIP +18%. SAPE +17%. PRSC +17%. MWW +17%. Midday top 10 Losers: CPRX -62%. BCRX -39%. COBR -24%. PRSS -21%. CALI -21%. UPG -20%. SVNT -19%. TRU -19%. MITK -19%. PANL -18%. Comment!
- Thursday, November 8, 2012, 9:49 AM BioCryst (BCRX) -41% after ending Phase III trials of its peramivir flu drug, as "the difference between peramivir and control groups for the primary endpoint was small." BioCryst received $234.8M from the federal Biomedical Advanced Research & Development Authority to help develop peramivir. The setback follows BioCryst last week withdrawing its IND application for its BCX5191 hepatitis C compound. (PR) Comment! [Healthcare, On the Move]
-
Thursday, November 8, 2012, 9:10 AM
Premarket gainers: DUSA +38%. MTSL +28%. USAT +15%. WLL +11%. ITMN +11%. SD +9%. QCOM +9%. THQI +8%. EZCH +7%. ALU +6%. MWW +7%. TTM +6%. DF +5%.
Losers: CPRX -56%. BCRX -34%. PANL -25%. SVNT -19%. SGEN -11%. MNST -10%. CNQR -9%. TNK -9%. NBG -8%. PSTI -8%. MAKO -7%. WINI -6%. AUI -5%. Comment! [On the Move] - Thursday, November 8, 2012, 6:13 AM BioCryst Pharmaceuticals (BCRX): Q3 EPS of -$0.19 beats by $0.02. Revenue of $5.8M (+11.5% Y/Y) beats by $1.2M. (PR) Comment! [Earnings, Healthcare]
- Thursday, November 8, 2012, 12:05 AM Notable earnings before Thursday’s open: AAP, AINV, AMRC, APU, BCRX, CNQ, DF, DUK, EBIX, ES, EZCH, FE, FSYS, GTXI, HK, KIOR, KSS, MFC, MWW, NOG, PGNX, PMT, POZN, PPL, SMBL, SNSS, SVNT, THI, TNK, VMC, WEN, WIN Comment! [Earnings]
- Wednesday, November 7, 2012, 5:30 PM Notable earnings before Thursday’s open: AAP, AINV, AMRC, APU, BCRX, CNQ, DF, DUK, EBIX, ES, EZCH, FE, FSYS, GTXI, HK, KIOR, KSS, MFC, MWW, NOG, PGNX, PMT, POZN, PPL, SMBL, SNSS, SVNT, THI, TNK, VMC, WEN, WIN 1 Comment [Earnings]
- Wednesday, October 31, 2012, 2:07 PM Shares of BioCryst Pharmaceuticals (BCRX -30%) react hard to yesterday's announcement, hitting new 52-week lows after the drug-maker withdrew its Investigational New Drug application for its antiviral nucleoside treatment for hepatitis C, BCX5191. The FDA has raised concerns related to the drug's preclinical toxicity profile at levels necessary for it to be effective. Comment! [Healthcare, On the Move]
-
- View all 1 replies
-
-
Justin M. Hall
CYCC, ARRY, IMGN, ALTH, BCRX => Notable Developments and Results 12/6/10 => Rx Investors.com => http://bit.ly/c9Kc5C - View all 0 replies
-
- View all 0 replies
-
AlphaLoboTrading
BCRX - 8.27 - at resistance levels, breakout watch, look for move above 8.40 as buy signal - View all 0 replies
-
AlphaLoboTrading
BCRX - 6.78 - on monthly support levels, would enter longs for move higher, stops below 6.00 - View all 0 replies
-
AlphaLoboTrading
BCRX - buy the dips, stock is in new uptrend and should continue to move higher to double digits. - View all 0 replies
-
- View all 0 replies
-
AlphaLoboTrading
BCRX - turn around in the making, look to go long on close above 7.00 or intraday break above 7.10 - View all 0 replies
-
Lakota Eagle
BCRX price pivot low entry with positive divergence near weekly support http://bit.ly/5qiK4F - View all 0 replies
-
John Mylant
If you missed it.... John's Covered Call Play Today- (BCRX) Sell Nov '09 10 for $1.05 for a 10.2% profot potential. http://bit.ly/GyiNm/ - View all 0 replies
LATEST REPLIES